Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial
- PMID: 33902836
- DOI: 10.1016/j.annemergmed.2020.12.016
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial
Comment in
-
[No title available]Ann Emerg Med. 2021 May;77(5):555-556. doi: 10.1016/j.annemergmed.2020.12.018. Ann Emerg Med. 2021. PMID: 33902835 No abstract available.
Comment on
-
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.Ann Emerg Med. 2021 Jun;77(6):613-619. doi: 10.1016/j.annemergmed.2020.08.021. Epub 2020 Nov 5. Ann Emerg Med. 2021. PMID: 33160719 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources